Leukemia, lymphoma, polycythaemia vera, myelodysplastic syndromes, other neoplasms of uncertain or unknown behavior of lymphatic, hematopoietic and related tissue, malignant immunoproliferative diseases, other and unspecified malignant neoplasms of lymphatic, hematopoietic and related tissue
Conditions
Interventions
Group 1: Exercise therapy intervention using whole-body electro myostimulation (WB-EMS training):
- starting before the allogeneic stem cell transplant, during the inpatient stay (once a week for 20 m
after discharge 1-2 times a week for 20 minutes
- intervention period: maximum of 18 weeks
Sponsors
Universitätsklinikum Würzburg, Medizinische Klinik II / CCC Mainfranken
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Age = 18 years - Patients who will receive an allogeneic stem cell transplantation - Performance Status according to Karnofsky >60% - signed declarations of consent and privacy policy of the study participant
Exclusion criteria
Exclusion criteria: - Operations in the last 2 months - abdominal hernia / inguinal hernia - Stents or bypasses inserted less than 6 months ago - Electrical implants, e.g. pacemaker, defibrillator - cardiac arrhythmia - Bleeding disorders, thrombocytopenia (<20,000/ul), other bleeding disorders (haemophilia) - Neuronal diseases, poorly controlled or recently diagnosed epilepsy - Large fluid accumulations in the body (e.g. abdominal fluid, ascites) - Open skin lesions, wounds, eczema, burns - Renal dysfunction - Current drinking restrictions (e.g. due to heart or kidney disease) - Participation in another exercise study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of measurement after each training session: - Feasibility and Safety of WB-EMS-based Exercise before, during and after an allogeneic stem cell transplant (FB1) Time of measurement after the inclusin of the study (T0) and after the inpatient stay (T1): - Hand strength (handgrip test) - general performance (6-min walk test) Time of measurement after the inclusin of the study (T0), after the inpatient stay (T1) and after the end of the intervention as a follow up (T2): - Fatigue (EORTC QLQ-FA12) - Quality of life (EORTC QLQ-C30) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of measurement after the inclusin of the study (T0) and after the inpatient stay (T1): - Preservation of muscle mass (bioimpedance analysis) - Preservation/improvement of muscle strength (chair-rising test) - Assessment of physical activity and sports in everyday life (BSA questionnaire), - Symptoms of cachexia (EORTC QLQ-CAX24) During the stay as part of the routine: - Documentation of clinical data: length of inpatient stay, complications, Karnofsky Index, Barthel Index | — |
Countries
Germany
Contacts
Public ContactClaudia;Annika Löffler;Gerspitzer
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II / CCC Mainfranken;Universitätsklinikum Würzburg; Comprehensive Cancer Center Mainfranken / Medizinische Klinik und Poliklinik II / Komplementäre Onkologie Integrativ (KOI)
Outcome results
None listed